Celldex Therapeutics (NASDAQ:CLDX) Trading Up 7.6%

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s share price was up 7.6% on Friday . The company traded as high as $2.71 and last traded at $2.68. Approximately 235,612 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 413,153 shares. The stock had previously closed at $2.49.

A number of analysts have weighed in on CLDX shares. ValuEngine upgraded Celldex Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 7th. HC Wainwright set a $19.00 price target on Celldex Therapeutics and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Finally, Zacks Investment Research upgraded Celldex Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 24th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $12.38.

The company has a fifty day moving average price of $2.87. The stock has a market capitalization of $36.90 million, a P/E ratio of -0.39 and a beta of 3.97. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.41 and a current ratio of 7.41.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.14) by $0.01. Celldex Therapeutics had a negative net margin of 729.59% and a negative return on equity of 45.09%. The company had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.26 million. As a group, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -4.8 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. Stratos Wealth Partners LTD. lifted its position in shares of Celldex Therapeutics by 2,400.0% during the 4th quarter. Stratos Wealth Partners LTD. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 240,000 shares during the period. Telemetry Investments L.L.C. raised its position in shares of Celldex Therapeutics by 87.2% during the 4th quarter. Telemetry Investments L.L.C. now owns 348,501 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 162,301 shares during the last quarter. Virtu Financial LLC raised its position in shares of Celldex Therapeutics by 72.2% during the 1st quarter. Virtu Financial LLC now owns 25,826 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 10,825 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Celldex Therapeutics by 9.0% during the 4th quarter. Geode Capital Management LLC now owns 1,119,913 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 92,792 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in Celldex Therapeutics by 26.5% in the 4th quarter. Acadian Asset Management LLC now owns 1,373,376 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 287,281 shares during the period. Institutional investors own 20.84% of the company’s stock.

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

See Also: Why Dividend Stocks May Be Right for You

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.